MedTrace Logo

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

NCT03833206 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.

Conditions

Interventions

DRUG

PDC-1421 Capsule

PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Sponsors & Collaborators

  • American BriVision Corporation

    collaborator UNKNOWN

  • BioLite, Inc.

    lead INDUSTRY

Principal Investigators

  • scott A Irwin, MD/PhD · Cedars-Sinai Health System

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-15
Primary Completion
2028-02-28
Completion
2028-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03833206 on ClinicalTrials.gov